You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients

    SBC: Oncoimmune Inc            Topic: 102

    Summary Although most COVID-19 patients exhibit mild to moderate clinical symptoms, a substantial portion require hospitalization with oxygen support. These patients are classified as having severe COVID-19 and have high risk of progression to an intensive care unit (ICU) with requirement for invasive mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and carry high risk for morta ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Telemetric Microsensor for Glaucoma

    SBC: H-CUBED            Topic: NEI

    PROJECT SUMMARY Glaucoma is an optic nerve disease in which there is progressive loss of retinal ganglion cells leading to irreversible loss of vision. It is estimated to affect 2% of the general population. More than 2.3 million Americans are affected with glaucoma and it is estimated to account for nearly $3B in direct medical costs. It is estimated that 4% of Caucasian patients and 8% of Africa ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Single-cell Phosphoprotein Assay to Evaluate Brain Tumor Therapeutic Resistance

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    Although signal transduction inhibitors occasionally offer clinical benefit for cancer patients, signal flux emanating from oncogenes is often distributed through multiple pathways, potentially underlying the resistance which causes failure of most such inhibitors. Measuring signal flux through multiple pathways, in response to signal transduction inhibitors, may help uncover network inter- action ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. 3D Holographic Guidance, Navigation, and Control (3D GNandC) for Endovascular Aortic Repair (EVAR)

    SBC: CENTERLINE BIOMEDICAL INC            Topic: NHLBI

    Project Summary/Abstract This SBIR Phase II project will advance the commercialization of our 3D guidance, navigation, and control (3D- GNC) system to improve stent-graft (SG) deployment during endovascular aortic aneurysm repair (EVAR) by overcoming limitations of 2D x-ray fluoroscopy (“fluoro”). 3D-GNC will increase safety, effectiveness, and efficiency as a result of better visualization, p ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Lateral flow immunoassay for rapid diagnosis of tinea capitis and onychomycosis

    SBC: DXDISCOVERY INC            Topic: NIBIB

    Tinea capitis (ringworm of the scalp) and onychomycosis (fungal nail infection) are infections that are most often caused by dermatophytes of the fungal genera Trichophyton and Microsporum. These two infections affect approximately 14 million people in the U.S. each year. Dermatophyte infections of the hair and nails are treated with oral antifungals for up to 12 weeks. Due to potential adverse ef ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Method for Efficiently and Robustly Retrieving Circulating miRNAs

    SBC: GLC Biotechnology, Inc.            Topic: 400

    Abstract This direct SBIR Phase II project aims to develop a novel technology and associated assays for efficiently and robustly extracting circulating miRNAs from blood (i.e. plasma or serum), which could transform the utility of miRNA testing in the diagnosis and monitoring of major diseases such as cancer and cardiovascular disease. Our competitive advantage lies in the ability to retrieve circ ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Automated Intravenous Anesthesia Delivery to Improve Outcome in Children-TIVAPeds

    SBC: NEUROWAVE SYSTEMS INC            Topic: 300

    SPECIFIC AIMS The overall objective of this Program is to develop the TIVAPeds, an anesthesia ‘auto-pilot’ drug delivery platform designed to administer Total Intravenous Anesthesia (TIVA) in children 2-yrs and older. The proposed platform integrates a brain monitor whose output is used to automatically and continuously adjust the delivery of propofol based on the care provider’s targeted ef ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A Single-Cell Proteomic instrument for Predictive Product Quality Check in Autologous CAR-T Immunotherapies

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    While CAR-T therapies have advanced in the clinic, there are still two specific issues using these breakthrough therapies for blood cancers: Durable responses in patients are only at 30-50% and Cytokine Release Syndrome occurs in 60-90% of treated patients. These limitations, for a drug that costs as much as $500,000, may cost an additional $250,000+ for treating adverse events leading to caution ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Multi-Omic Single-Cell System for Improved Combination Cancer Immunotherapy Monitoring and Implementation

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    IsoPlexis proposes to deliver a novel multi-omic method for targeted profiling of both the TCR sequence and proteome from an array of 1000+ single cells. Specifically, we will deliver a single-cell, TCR sequencing and protein capture assay for identifying responsive antigen specific TCRs, and concurrently evaluate these T-cells for functional response to that antigen. The challenge remains to link ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Developing, Testing and Validating a Wearable Alcohol Biosensor

    SBC: Clinitech, LLC            Topic: 450

    1 PROJECT SUMMARY2 This application for a Phase II SBIR award extends the successful completion of Phase I and represents a 3 collaboration between Clinitech, LLC and McLean Hospital/Harvard Medical School to continue the4 development of a wearable biosensor for detecting alcohol in the interstitial fluid of humans. Excessive use of5 alcohol accounts for much of the public health burden related to ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government